ZILA Zila (MM)

Zila, Inc. (NASDAQ GM: ZILA) has appointed David R. Bethune as the Chairman of the Board of Directors effective May 21, 2007. He replaces Douglas D. Burkett, Ph.D., who will continue as Chief Executive Officer, President and a Director. Mr. Bethune, 65, has been on Zila�s board since 2005 and has spent over 40 years in the pharmaceuticals industry. Mr. Bethune has served as a Board member of many companies and associations, including Elan Corporation, the National Pharmaceutical Council and the American Cancer Society Foundation. Most recently, Mr. Bethune was Chairman and Chief Executive Officer of Atrix Laboratories, a drug delivery and product development company. Prior to Atrix Laboratories, he was President and Chief Operating Officer of IVAX Corporation, a pharmaceutical company. Before joining IVAX, he began a start-up pharmaceutical company venture formed by Mayo Medical Ventures, a business unit of Mayo Clinics of Rochester. He previously served at Cyanamid Company, as Group Vice President of North American Operations and as a member of the company�s Executive Committee, where he had authority for human biologics, consumer health products, pharmaceuticals and ophthalmics, as well as global medical research. Mr. Bethune was also President of the Lederle Laboratories Division of American Cyanamid Company and President of G.D. Searle�s North American operations. Mr. Bethune received a B.A. degree in accounting and economics from Lenior-Rhyne College, Hickory, North Carolina and Masters in Business Administration in the Executive Program from Columbia University Graduate School. In addition, David has served on a number of non-profit and social services organizations including the Hill Country Community Needs Counsel. Douglas D Burkett, Chief Executive Officer and President, commented �David Bethune has vast experience in creating shareholder value within healthcare companies and has contributed to Zila�s Board since he joined in December of 2005. We look forward to working with David in his new capacity as Company Chairman.� The Company also announced yesterday the resignation of Kurt R. Krauss from the Board of Directors. For additional information see the Company�s Form 8-K filed with the Securities and Exchange Commission on May 21, 2007. About�Zila, Inc. Zila, Inc., headquartered in Phoenix, is a leading�oral cancer diagnostic company�focused on the prevention and treatment of oral disease: Zila is dedicated to establishing ViziLite� Plus as the new standard of care within the medical community for the early detection of oral abnormalities that could lead to cancer, with�an initial focus on the dental market through Pro-Dentec�, a leading designer, manufacturer and marketer of Soft Tissue Management (STM�) products. Sold�exclusively�and directly to dental professionals, Pro-Dentec's core products include the Rota-dent� Professional Powered Brush, the Pro-Select3� Piezo-Ultrasonic Scaler System and a suite of pharmaceutical STM� products for both in-office and home-care use. Zila is also focused on achieving regulatory approval for the next generation oral cancer diagnostic, OraTest�, followed by the development of additional applications of its cancer detection technologies. For more information about Zila, visit www.zila.com. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate, and we disclaim any obligation to update or revise any such forward-looking statements. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to the documents we file with the Securities and Exchange Commission, including our Form 10-K for the fiscal year ended July 31, 2006, our Current Report on Form 8-K filed on December 28, 2006, and our Form 10-Q for the quarter ended January 31, 2007.